Clinical trials: Chemoradiotherapy
Rectal Cancer
Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial
To determine the maximum tolerated dose (MTD) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.
- Trial name
- DREAMtherapy (NCT01160926)
- Testing
- AZD6244, Cediranib (AZD2171)
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- The Christie NHS Foundation Trust
Pancreatic Carcinoma
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
This is a prospective, randomized phase II trial. The aim of this study is to assess the efficacy of two therapeutics strategies.
- Trial name
- NCT02676349
- Testing
- mFolfirinox, Chemoradiotherapy, surgery
- Where
- 26 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut de Cancérologie de Lorraine
Lung Cancer
A Remotely Supervised Exercise Program for Lung Cancer Patients Undergoing Chemoradiation (REM)
The purpose of this study is to conduct a pilot randomized controlled trial (RCT) evaluating the feasibility and potential effectiveness of a remotely supervised exercise program (REM) in promoting adherence to an exercise…
- Trial name
- NCT03500393
- Testing
- Remotely Supervised Exercise (REM), Unsupervised Exercise (UNSUP)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Locally Advanced Rectal Cancer (LARC)
Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
This study explores the key clinical issues in the field of neoadjuvant therapy for locally advanced rectal cancer. There are three core problems with the currently recommended total neoadjuvant therapy (TNT) in the guidelines…
- Trial name
- STELLARIII (NCT07040098)
- Testing
- Sintilimab, Short-course radiotherapy, Long-course concurrent chemoradiotherapy
- Where
- 2 sites in China
- Volunteers
- 228 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00025298
- Testing
- amifostine trihydrate, carboplatin, cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma, Astrocytoma, Grade III
Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas
Several investigations suggest neural stem cells located in the subventricular region play an active role in promoting or even initiating cortical malignant glioma growth.
- Conditions
- Glioblastoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Malignant Glioma
- Trial name
- NCT03956706
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Sponsor
- Northwell Health
Locally Advanced Rectal Cancer
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
This is a multicenter, prospective, randomized controlled study to evaluate the effectiveness and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and PCSK9 inhibitor in the treatment of patients with pMMR/MSS…
- Trial name
- NCT06304987
- Testing
- Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor, Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Beijing Friendship Hospital
Pancreatic Adenocarcinoma Non-resectable
PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.
- Trial name
- HALO-IST (NCT02910882)
- Testing
- PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Scripps Health
Radiotherapy, Radiation-Induced Complications
A Prospective, Single-Arm Clinical Study of a Dietary Supplement for the Prevention of Acute Radiation-Induced Rectal Injury During Neoadjuvant Chemoradiotherapy for Rectal Cancer
This clinical study is a prospective, single-arm, single-center trial aimed at assessing the safety and efficacy of tributyrin (TB) as a dietary supplement for preventing acute radiation-induced rectal injury (ARII).
- Trial name
- NCT07802002
- Testing
- Tributyrin
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Nasopharyngeal Carcinoma, Induction Chemotherapy
Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
To evaluate the long-term locoregional control, survival rate, late toxicity and quality of life after reducing the target volume in patients with locoregionally advanced nasopharyngeal carcinoma patients treated with induction…
- Conditions
- Nasopharyngeal Carcinoma, Induction Chemotherapy, Radiotherapy
- Trial name
- NPC-GTV (NCT04384627)
- Testing
- Delineating the GTV according to the pretreatment or post-IC tumor extension
- Where
- 2 sites in China
- Volunteers
- 445 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Oral Mucositis
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
GTI-4419-202 is a Phase 2 open-label study of the effects of GC4419 (IV) when administered in combination with IMRT and cisplatin to up to subjects with head and neck cancer, who are at high risk for Severe Oral Mucositis (SOM)
- Trial name
- NCT04529850
- Testing
- Drug: GC4419, Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 24 sites in Belgium, Czechia and 4 more
- Volunteers
- 38 people
- Sponsor
- Galera Therapeutics, Inc.
Rectal Neoplasms, Rectal Cancer Stage II
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
Preoperative 5-FU-based (5-fluorouracil) chemoradiotherapy (CRT), total mesorectal excision surgery, and 4 cycles of adjuvant 5-FU - as established by CAO/ARO/AIO-94 - is at present a standard of care for patients with locally…
- Conditions
- Rectal Neoplasms, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- CAOAROAIO-12 (NCT02363374)
- Testing
- Induction Chemotherapy arm A, Radiation arm A, Radiation arm B
- Where
- 20 sites in Germany
- Volunteers
- 311 people
- Sponsor
- Prof. Dr. med. Claus Rödel
Cancer Patients Receiving Chemotherapy or Chemoradiotherapy
Nutrition Intervention During Chemotherapy
Weight loss and muscle wasting commonly occurs in patients with cancer, negatively influencing their quality of life, treatment response and survival.
- Trial name
- NCT01871350
- Testing
- Daily intake for 10 weeks (+/- 2 weeks)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Extrahepatic Bile Duct Cancer, Nausea
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer.
- Conditions
- Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer
- Trial name
- NCT01534637
- Testing
- aprepitant, gemcitabine hydrochloride, capecitabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University Health Sciences
Non Small Cell Lung Cancer
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
To evaluate the efficacy and safety adebrelimab in Combination with chemotherapy after 3 cycles as neoadjuvant therapy and surgery or chemoradiotherapy based on MDT compared with adebrelimab after chemoradiotherapy in potentially…
- Trial name
- NCT06424899
- Testing
- Adebrelimab, radical chemoradiotherapy, Platinum based chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zeng Jian
Lung Cancer
CLEAR-Lung III: Circulating Tumor DNA-Guided Consolidation Chemotherapy and Immunotherapy
CLEAR LUNG-III is a single-arm, phase II study evaluating a circulating tumor DNA (ctDNA)-guided treatment strategy in patients with unresectable stage III non-small cell lung cancer who have completed definitive chemoradiation…
- Trial name
- NCT07858253
- Testing
- Consolidation Chemotherapy
- Volunteers
- 43 people
- Sponsor
- Anusha Chidharla, MD
Esophageal Neoplasms, Carcinoma, Squamous Cell
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
To study the safety and feasibility of stereotactic radiation dose escalation following neoadjuvant chemotherapy with concurrent conventionally fractionated radiation, by evaluating the acute and late toxicity of treatment.
- Conditions
- Esophageal Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00368329
- Testing
- Capecitabine (Xeloda), [18-F] Fluorodeoxyglucose (FDG), 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Head and Neck Cancer
Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT
Primary Objective: To evaluate the population prevalence of critical body weight loss ( more than 5% from baseline) in patients with Head and Neck cancer.
- Trial name
- NCT02980653
- Testing
- Megestrol acetate (MA) 400 mg/day
- Where
- Taiwan
- Volunteers
- 105 people
- Sponsor
- TTY Biopharm
Pancreatic Cancer
Valproic Acid With Chemoradiotherapy for Pancreatic Cancer
This is non-randomized phase 2 study to evaluate toxicity and efficacy of valproic acid (VA) with concurrent chemoradiotherapy (CCRT) containing weekly gemcitabine in patients with unresectable locally advanced pancreatic cancer…
- Trial name
- NCT01333631
- Testing
- Valproic acid
- Volunteers
- 20 people
- Sponsor
- Soroka University Medical Center
Colorectal Cancer
Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PETACC-6 (NCT00766155)
- Testing
- capecitabine, oxaliplatin
- Volunteers
- 1,094 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.